Calcium ascorbate 550mg tablets

The present study tested the efficacy of 24-epibrassinolide (EBL) and calcium (Ca) for mediating salinity tolerance in tomato. Salinity stress affected the morphological parameters of tomato as well as leaf relative water content (LRWC), photosynthetic and accessory pigments, leaf gas exchange parameters, chlorophyll fluorescence and the uptake of essential macronutrients. The salt (NaCl) treatment induced oxidative stress in the form of increased Na+ ion concentration by 146%, electrolyte leakage (EL) by 61.11%, lipid peroxidation (MDA) 167% and hydrogen peroxide (H2O2) content by 175%. Salt stress also enhanced antioxidant enzyme activities including those in the ascorbate–glutathione cycle. Plants treated with EBL or Ca after salt exposure mitigated the ill effects of salt stress, including oxidative stress, by reducing the uptake of Na+ ions by 52%. The combined dose of EBL + Ca reversed the salt-induced changes through an elevated pool of enzymes in the ascorbate–glutathione cycle, other antioxidants (superoxide dismutase, catalase), and osmoprotectants (proline, glycine betaine). Exogenously applied EBL and Ca help to optimize mineral nutrient status and enable tomato plants to tolerate salt toxicity. The ability of tomato plants to tolerate salt stress when supplemented with EBL and Ca was attributed to modifications to enzymatic and non-enzymatic antioxidants, osmolytes and metabolites.

Abstract licence: CC BY 4.0

Sepsis remains the leading cause of death in intensive care units globally, with catecholamine-resistant shock posing a persistent therapeutic challenge. Norepinephrine is the primary vasopressor used to treat hypotension in sepsis, but its efficacy is often limited by multifactorial loss of pressor responsiveness, including adrenergic receptor desensitisation, excess nitric oxide, systemic inflammation, and endothelial injury. Ascorbate (vitamin C) has emerged as a potential adjunct therapy because it supports endothelial function, reduces oxidative stress, activates the immune system and enhances endogenous vasopressor synthesis. Despite restoration of systemic hemodynamics with fluids and vasopressors, the frontal cortex remains particularly vulnerable to microcirculatory ischemia and hypoxia, contributing to sepsis-associated encephalopathy through hypoperfusion, hypoxia, hyperthermia, oxidative stress, neuroinflammation, and mitochondrial dysfunction, ultimately leading to neuronal injury and delirium. Plasma levels of ascorbate are profoundly depleted in sepsis and correlate with disease severity. Cerebral cortical neurons actively concentrate ascorbate at levels up to 250-fold higher than plasma, underscoring its importance in maintaining redox homeostasis and metabolism in the brain. While the conventional intravenous vitamin C formulation, ascorbic acid, has been associated with harm in clinical trials, emerging preclinical and early clinical data suggest that intravenous sodium ascorbate, a pH–neutral formulation of vitamin C, may restore noradrenaline sensitivity and re-establish frontal cortical microvascular perfusion and oxygenation. This review discusses the mechanistic rationale and therapeutic potential of sodium ascorbate in sepsis, including its ability to cross the blood-brain barrier. By stabilising cardiovascular and cerebrovascular function, sodium ascorbate may represent a promising adjunctive therapy to improve the management of sepsis.

Abstract licence: CC BY-NC-ND

Due to the essential requirement of vitamin C (ascorbate) by humans, formulation of the vitamin to increase its bioavailability is of relevance, particularly for those with higher requirements for the vitamin. In this scoping review, studies assessing the bioavailability of liposomal versus non-liposomal ascorbate were identified through database and manual searching and relevant pharmacokinetic data were extracted. Of the 321 studies identified, 10 were included in the final review. Seven of the trials used randomised crossover designs, one used parallel groups and two were non-randomised. Vastly different liposomal formulations, ascorbate doses (0.15-10 g) and sample collection durations (4-24 h) were used, thereby making it difficult to directly compare the studies. Nevertheless, nine of the studies showed higher bioavailability of liposomal versus non-liposomal ascorbate: 1.2-5.4-fold higher Cmax and 1.3-7.2-fold higher AUC. However, none of the studies assessed ascorbate elimination; therefore, it is uncertain whether the ratios of liposomal to non-liposomal ascorbate in urine are equivalent to those observed in plasma. Furthermore, only two of the studies assessed in vivo cellular uptake and only two assessed potential biological effects. Thus, future studies should include urinary elimination and cellular uptake kinetics, assess participants with low baseline status and investigate potential biological effects. SUMMARY: Due to the essential requirement of vitamin C by humans, formulations to increase its uptake into the body are of relevance, particularly in those with higher requirements for the vitamin. In this review, studies assessing the uptake of liposomal versus non-liposomal vitamin C were investigated; liposomal vitamin C comprising the vitamin encapsulated within lipids. Ten studies were identified, which administered different liposomal formulations, vitamin C doses (0.15-10 g) and sample collection durations (4-24 h). Nine of the studies showed higher uptake of liposomal vitamin C. Future studies should assess urinary excretion, cellular uptake and biological effects of liposomal vitamin C.

Abstract licence: CC BY-NC-ND

Dentin deproteinization strategies are being revisited as adjunctive approaches to reduce technique sensitivity, improve monomer infiltration to mineralized dentin, and enhance the longevity of resin-dentin interfaces. This organized narrative review critically summarizes the chemistry, kinetics, biological considerations, and clinical translatability of agents used for smear-layer deproteinization or post-etching deproteinization. Searches of PubMed/MEDLINE, Scopus, and LILACS up to October 2025 were used to identify evidence on oxidizing irrigants (sodium hypochlorite/hypochlorous acid, calcium hypochlorite, peracetic acid, chlorine dioxide), enzymatic proteolysis treatments (bromelain, papain, trypsin/pepsin, and GAG-targeting enzymes), physical approaches (heat and lasers), and post-oxidizer reducing/antioxidant strategies. Oxidizers provide the fastest and most surface-verified organic removal, but their clinical value is limited by concentration- and time-dependent oxidative carry-over, which interferes with free-radical polymerization. Enzymes offer a more selective route, although their support is driven largely by bond strength and morphological outcomes rather than direct surface-chemical confirmation. Heat remains a proof-of-principle method rather than a clinical option, whereas laser protocols are highly parameter-sensitive. Overall, deproteinization should be interpreted through a combined framework of surface chemistry, adhesive compatibility, aging behavior, biosafety, and chairside feasibility. Current evidence supports cautious, protocol-specific development rather than routine clinical adoption, with priority given to clinically realistic time-dose windows and paired surface/aging outcomes.

Abstract licence: CC BY